Document is current

Article History

Received: 29 October 2021

Revised: 26 January 2022

Accepted: 1 February 2022

First Online: 21 March 2022

Competing interests

: The authors declare the following competing interests: S.S.N., consulting fees or honorarium from Kite, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, Unum Therapeutics, Bluebird Bio, Medscape, Aptitude Health, Bio Ascend and MJH Life Sciences; personal fees from Kite, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene, Kuur, Incyte, Precision BioSciences, Legend, Adicet Bio, Calibr and Unum Therapeutics; grants, contracts or research funding from Kite, Bristol Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics (Cogent Biosciences), Allogene, Precision BioSciences, Acerta and Adicet Bio; and intellectual property from Takeda Pharmaceuticals and related to cell therapy. M.D., honoraria from Roche, Gilead, MSD and Novartis; consultancy or advisory role for Roche, Gilead, MSD and Novartis; speakers’ bureau participation for Roche, Gilead, MSD and Novartis; and research funding from Novartis and Roche. J.M., honoraria from Targeted Oncology, OncView, Curio, Kyowa Kirin, Physicians’ Education Resource and Seagen; consultancy or advisory role for Pharmacyclics/AbbVie, Bayer, Kite, Pfizer, Janssen, Juno/Celgene, Bristol Myers Squibb, Kyowa Kirin, Alexion, Fosun Kite, Innovent, Seagen, BeiGene, Debiopharm, Epizyme, Karyopharm, ADC Therapeutics, Servier and Genmab; speakers’ bureau participation for Kite, Kyowa, Bayer, Pharmacyclics/Janssen, Seagen, Acrotech/Aurobindo, Beigene, Verastem, AstraZeneca, Celgene/Bristol Myers Squibb and Genentech/Roche; and research funding (payed to institution) from Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seagen, Janssen and Millennium. M.L.U., Advisory Board of Gilead and Stemline. C.T., honoraria from Bristol Myers Squibb/Celgene, AbbVie, Takeda, Novartis, Roche, Kite, and Incyte; consultancy or advisory role for Bristol Myers Squibb/Celgene, AbbVie, Takeda, Roche, Novartis, Kite, and Incyte; and travel support from Bristol Myers Squibb/Celgene, Takeda, Roche, Novartis, and Kite. O.O.O., consultancy or advisory role for Kite, Janssen, Pfizer, Novartis and Curio Science; honoraria and research funding from Kite. A.F.H., consultancy or advisory role for Bristol Meyers Squibb, Merck, Genentech, Seagen, AstraZeneca, Karyopharm, ADC Therapeutics, Takeda and Tubulis; and research funding from Bristol Myers Squibb, Merck, Genentech, Seagen, Kite, Gilead Sciences, AstraZeneca, Karyopharm and ADC Therapeutics. C.S.U., consultancy or advisory role for Atara and Kite; research funding and travel expenses from Kite. Y.L., consultancy or advisory role for Kite, Janssen, Novartis, Celgene, Bluebird Bio, Juno, Legend, Sorrento, Gamida Cell and Vineti; and research funding from Kite, Janssen, Celgene, Bluebird Bio, Merck and Takeda. P.A.R., honoraria from Novartis; consultancy or advisory role for Novartis, Celgene/Bristol Myers Squibb, Takeda, BeiGene and Karyopharm Therapeutics; speakers’ bureau participation for Kite; and research funding from Kite, Celgene/Bristol Myers Squibb, Novartis, Calibr, Xencor, MorphoSys and Tessa Therapeutics. N.K., consulting or advisory role and honoraria from Gilead, Novartis and Celgene. S.d.V., participation on a Data Safety Advisory Board for BeiGene. C.L., employment with and travel support from Kite; stock or other ownership in Gilead Sciences. F.M., employment with Kite; and stock or other ownership in Gilead. J.D., employment with Kite; stock or other ownership in Gilead Sciences; consultancy or advisory role for and intellectual property from GliaCure/Tufts. H.X., employment with Kite. J.C.C., consultancy fees for Kite, AbbVie, Janssen, ADC Therapeutics, Karyopharm, Kymera, GenMab and Novartis; speakers’ bureau participation for Morphosys, Epyzime, Bristol Myers Squibb, BeiGene and AstraZeneca; and research funding from AstraZeneca, Merck, ADC Therapeutics and Adaptive.